Pareto Securities Healthcare Conference: Sedana Medical's inhaled sedative drug/device combo is currently in front of FDA - they hope to change the ICU with it
CEO Johannes Doll describes what he believes are the advantages of an inhaled sedative vs the traditional IV. The company already has experience commercializing this in Europe, with 1 out of 7 ICU patients in Germany currently using it. The U.S. PDUFA date is April 16.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.